All News

Abbisko will utilize its drug development platform and R&D ecosystem to develop drug targets determined by Lilly.

Aprecia’s president and COO discusses the benefits of using 3D printing technology to quickly produce high quality drug tablet in a variety of dosages.

Examining the drivers of 340B drug program growth, the impact of vertical integration and contract pharmacies, the ongoing legal and regulatory disputes, and the strategic considerations life sciences companies must navigate in this evolving landscape.

In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim its footing in global clinical research, market access expert Manasi Salgaonkar explains why Class of Trade classification is becoming one of the hardest — and most consequential — problems in pharmaceutical commercial operations, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on how DARPA's EQUIP-A-Pharma program is using federal investment to incentivize the reshoring of drug manufacturing to the United States.

Consolidation, specialty growth, and integrated networks are multiplying the entities manufacturers must classify, just as the IRA, 340B, and Medicaid rules raise the cost of getting any one of them wrong.

FDA plans a pilot to shorten early-stage drug trial timelines, raising strategic questions for biopharma development and investment.

Kyle Smith, president and COO of Aprecia, explains how the EQUIP-A-Pharma program is promoting the reshoring of pharma and biotech manufacturing.

Clinical Affairs supports responsible promotion through scientific validation, cross-functional collaboration, and oversight of both traditional and digital communications.

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico Medicine enters an AI-powered drug discovery collaboration with SK Biopharmaceuticals valued at up to $2.5 billion to advance neuroimmune treatments in the central nervous system, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on the real-world benefits and persistent challenges of operating as a fully domestic manufacturer in an era of tariffs and supply chain pressure.

The acquisition will bolster AbbVie’s pipeline, including the addition of monoclonal antibody treatment zumilokibart.

Aprecia’s president and COO Kyle Smith explains the challenges domestic manufacturers face when sourcing certain API and materials.

In today's Pharmaceutical Executive Daily, an FDA advisory committee votes unanimously in favor of the benefit-risk profile of Moderna's investigational mRNA-1010 seasonal influenza vaccine across both younger and older adult populations, a pharma funding roundup covers Kardigan's upsized $400 million IPO debut on Nasdaq and cAMPfield Therapeutics' $180 million Series A launch, and Pharmaceutical Executive speaks with Brian Hilberdink of Boehringer Ingelheim on redefining what success looks like in obesity care in the GLP-1 era.

Kardigan priced its cardiovascular IPO at $400 million and surged 31% on its Nasdaq debut, while cAMPfield Therapeutics launched the same week with a $180 million Series A to advance prifemilast.

FDA advisory panel voted 9-0 to recommend approval of Moderna's mRNA flu vaccine mRNA-1010 across both the 50-to-64 and 65-and-older age groups, a unanimous outcome that validates the underlying clinical data.

Kyle Smith, president and COO of Aprecia, discusses how additive manufacturing allows for the rapid development and manufacturing of a variety of dosage forms.

As GLP-1 therapies reshape obesity care, Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues that lasting progress depends on targeting metabolic health, not just the number on the scale.

In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biotech RayThera, FDA approves Utebzi as the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections, and FDA expands the indication for Merck's Capvaxive to include children and adolescents aged 2 through 17 with chronic medical conditions at increased risk for pneumococcal disease.

FDA has expanded Capvaxive's indication to high-risk children and adolescents aged 2 through 17 who have completed a primary pneumococcal series, making it the only conjugate vaccine in the U.S. specifically studied and approved for this population.

FDA has approved Utebzi as the first oral carbapenem antibiotic for complicated urinary tract infections, giving patients and providers an alternative to intravenous-only carbapenem therapy.

Biogen has agreed to acquire private immunology biotech RayThera for up to $1 billion, adding a suite of undisclosed small molecule anti-inflammatory candidates to its pipeline.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains what sets his company's obesity strategy apart in an increasingly crowded field.

Marketers must navigate a new landscape that sees customers expecting highly-personalized experiences that mirror their experiences with non-health brands.

Novavax’s EVP of corporate affairs and head of its Sweden division discusses new vaccine technologies, such as its adjuvant matrix technology, are bringing new players into the space.

In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu vaccine, a pharma roundup covers Merck's $510 million collaboration with Protillion Biosciences and Jazz Pharmaceuticals' multi-program antibody discovery deal with AbCellera, and Jack McFeely argues that behavioral and engagement insights are the missing ingredient in patient support programs that struggle to sustain long-term persistence.

As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel question: can "Healthcare Stewardship Capital" reconcile investor returns with patient welfare?

FDA scientists have flagged evidence gaps in Moderna's mRNA flu vaccine mFlusiva ahead of an advisory committee vote, raising questions about its performance across influenza strains, high-risk patient subgroups, and co-administration scenarios.

Protillion Biosciences and AbCellera each secured platform-based drug discovery deals this week, with Protillion partnering with Merck on multi-target protein engineering in a deal worth up to $510 million and Jazz Pharmaceuticals committing up to $84 million upfront to AbCellera for T-cell engaging multispecific antibodies in gastrointestinal cancers.

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, notes how the real obstacle in obesity care isn't how a drug is delivered, it's whether patients stay on treatment long enough to achieve lasting metabolic health.